'Dual circulation' to boost growth (VI)

A1: We're dedicated to the China market, which has huge unmet demand for available, accessible and affordable high-quality medical solutions. In such a special year as 2020, GSK continued to be actively engaged in the battle against the COVID-19 pandemic, providing patented technology, establishing extensive strategic partnerships around the world, and supporting the development, manufacture and launch of COVID-19 vaccines.

A2: China's dual-circulation strategy allows the sharing of market opportunities and innovative results, bringing opportunities for mutual benefits. GSK is stepping up efforts in China to introduce innovative healthcare solutions and improve accessibility.

Over the past 10 years, GSK has launched nearly 20 biopharmaceutical products in China. In 2020, three of our innovative products have been successfully added to the National Reimbursement Drug List to benefit Chinese patients. We will continue to leverage our advantages and expertise to bring more of our innovative medicines and vaccines to the country addressing the huge unmet medical needs.

A3: Our mission of bringing innovative healthcare and medical solutions to China will especially benefit from increasing stability in foreign investments, trade and supply chains. This will help us further add to the suite of products that we have launched here, as we up the pace of introducing innovative vaccines, prescribed drugs and new healthcare products into the China market.

A4: China's swift and effective measures against the COVID-19 pandemic convinced the world of their technical capabilities and social resilience. As the second-largest economy globally, its speedy recovery in almost all aspects of life reassured our business operation and long-term development strategy in China, especially for the pharmaceutical industry, with COVID-19 calling for improving attention and investment in healthcare.

A5: In pursuing the new development pattern, scientific and technological innovation is the key to creating new growth momentum. Underpinned by scientific and technological innovation, China's "new development stage" encourages GSK's mission and strategy to strengthening our R&D efforts and investments to bring more healthcare innovations to China.

A7: The Healthy China 2030 Vision will continue to be our utmost focus. Besides an increased attention to public health and strengthening the early response system, we foresee rapid development in preventive healthcare, telemedicine and promotion of elderly care.

To that end, GSK continues to be instrumental in supporting the development, manufacture and launch of COVID-19 vaccines and treatments. Besides generating medical innovations, GSK is also striving to build a health management ecosystem that integrates preventive measures and treatment, aiming to increase the accessibility of high-quality innovative drugs and vaccines, improve overall diagnosis and treatment in China's medical and healthcare industry, and help Chinese people to "do more, feel better and live longer".